表紙:肺疾患向けドラッグデリバリーシステム市場: 製品タイプ、用途、地域別 - 市場規模、シェア、見通し、および機会分析
市場調査レポート
商品コード
948391

肺疾患向けドラッグデリバリーシステム市場: 製品タイプ、用途、地域別 - 市場規模、シェア、見通し、および機会分析

Pulmonary Drug Delivery Systems Market, By Product Type, By Application, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版日: | 発行: Coherent Market Insights | ページ情報: 英文 178 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=128.03円
肺疾患向けドラッグデリバリーシステム市場: 製品タイプ、用途、地域別 - 市場規模、シェア、見通し、および機会分析
出版日: 2020年06月30日
発行: Coherent Market Insights
ページ情報: 英文 178 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

肺疾患向けドラッグデリバリーシステムには、経口吸入・経鼻薬(OINDP)、定量投与(MDI)、乾燥粉末吸入器(DPI)、点鼻スプレー、ネブライザーなどが挙げられ、すべての吸入製品は、抽出物、浸出物、微生物汚染物質の検査が義務付けられています。世界の肺疾患向けドラッグデリバリーシステム市場の予測期間中における抑制要因には、厳格な規制と使用中の合併症が挙げられます。

当レポートは、世界の肺疾患向けドラッグデリバリーシステム市場について調査しており、市場機会や動向、成長および抑制要因、製品タイプ・用途・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 調査の目的と前提条件

第2章 市場の展望

  • レポートの概要
  • 市場の定義と範囲
  • エグゼクティブサマリー
  • 市場内訳 : 製品タイプ別
  • 市場内訳 :用途別
  • Coherent Opportunity Map (COM)

第3章 市場力学、規制、 動向分析

  • 市場力学
  • 成長要因
  • 抑制要因
  • 市場機会
  • 影響分析
  • 主な発展
  • 技術進歩
  • 規制シナリオ

第4章 市場分析:製品タイプ別

  • イントロダクション
  • 市場シェア分析
  • 前年比成長分析
  • セグメント動向
  • ネブライザー
  • MDI
  • DPI

第5章 市場分析:用途別

  • イントロダクション
  • 市場シェア分析
  • 前年比成長分析
  • セグメント動向
  • 喘息
  • COPD
  • 嚢胞性線維症

第6章 市場分析:地域別

  • イントロダクション
  • 市場シェア分析
  • 前年比成長分析
  • セグメント動向
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東
  • アフリカ

第7章 競合情勢

  • 企業プロファイル
  • 3M Health Care
  • Allied Healthcare Products, Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim
  • CareFusion Corporation
  • GF Health Products, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • Omron Healthcare, Inc.(オムロン株式会社)

第8章 セクション

  • 参考文献
  • 調査手法
  • 当社について
目次

Title:
Pulmonary Drug Delivery Systems Market, By Product Type (Nebulizers, MDIs, DPIs), By Application (Asthma, COPD, Cystic Fibrosis), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Orally inhaled and nasal drug products (OINDPs) are the products which include metered dose (MDIs), dry powder inhalers (DPIs), nasal sprays and nebulizers. According to FDA, respiratory inhalers are classified under Class II medical devices. All inhaled products have to undergo mandatory test for extractables, leachables and microbial contaminants. Specific tests for OINDPs include aerodynamic particle size distribution (APSD) and delivered dose uniformity (DDU). These tests are regarded as key parameters for assessing performance of the OINDPs. In addition, nasal sprays and MDIs are supplemented by tests to monitor the performance of the actuator and metering valve such as plume geometry and spray pattern.

Restraints of the Global Pulmonary Drug Delivery Systems Market

Major factors hampering the growth of the pulmonary drug delivery systems market during the forecast period constitutes of stringent regulations, and complications in use.

Key features of the study:

  • This report provides in-depth analysis of the global pulmonary drug delivery systems market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019-2027), considering 2018, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global pulmonary drug delivery systems market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include 3M Health Care, Allied Healthcare Products, Inc., AstraZeneca plc, Boehringer Ingelheim, CareFusion Corporation, GF Health Products, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals, PARI Respiratory Equipment, Inc., and Philips Healthcare.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global pulmonary drug delivery systems market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Pulmonary Drug Delivery Systems Market, By Product Type:
    • Nebulizers
    • MDIs
    • DPIs
  • Global Pulmonary Drug Delivery Systems Market, By Application:
    • Asthma
    • COPD
    • Cystic Fibrosis
  • Global Pulmonary Drug Delivery Systems Market, By Geography:
    • North America
    • By Product Type
  • Nebulizers
  • MDIs
  • DPIs
    • By Application
  • Asthma
  • COPD
  • Cystic Fibrosis
    • By Country:
  • U.S.
  • Canada
    • Europe
    • By Product Type
  • Nebulizers
  • MDIs
  • DPIs
    • By Application
  • Asthma
  • COPD
  • Cystic Fibrosis
    • By Country:
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
    • Asia Pacific
    • By Product Type
  • Nebulizers
  • MDIs
  • DPIs
    • By Application
  • Asthma
  • COPD
  • Cystic Fibrosis
    • By Country:
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
    • Latin America
    • By Product Type
  • Nebulizers
  • MDIs
  • DPIs
    • By Application
  • Asthma
  • COPD
  • Cystic Fibrosis
    • By Country
  • Brazil
  • Argentina
  • Mexico
  • Rest of LATAM
    • Middle East:
    • By Product Type
  • Nebulizers
  • MDIs
  • DPIs
    • By Application
  • Asthma
  • COPD
  • Cystic Fibrosis
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
    • Africa
    • By Product Type
  • Nebulizers
  • MDIs
  • DPIs
    • By Application
  • Asthma
  • COPD
  • Cystic Fibrosis
    • By Country/Region:
  • Central Africa
  • South Africa
  • North Africa
  • Company Profiles
    • 3M Health Care*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Key Strategies
    • Recent Developments
    • Allied Healthcare Products, Inc.
    • AstraZeneca plc
    • Boehringer Ingelheim
    • CareFusion Corporation
    • GF Health Products, Inc.
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Novartis AG
    • Omron Healthcare, Inc.
    • Glenmark Pharmaceuticals
    • PARI Respiratory Equipment, Inc.
    • Philips Healthcare

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

    • Research Objectives
    • Assumptions
    • Abbreviations

2. Market Purview

    • Report Description
    • Market Definition and Scope
    • Executive Summary
    • Market Snippet, By Product Type
    • Market Snippet, By Application
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Technological Advancement
    • Regulatory Scenario

4. Global Pulmonary Drug Delivery Systems Market, By Product Type, 2017 - 2027 (US$ Mn)

    • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2019-2027
    • Segment Trends
    • Nebulizers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Mn)
    • Segment Trends
    • MDIs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Mn)
    • Segment Trends
    • DPIs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Mn)
    • Segment Trends

5. Global Pulmonary Drug Delivery Systems Market, By Application, 2017 - 2027 (US$ Mn)

    • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2019-2027
    • Segment Trends
    • Asthma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Mn)
    • Segment Trends
    • COPD
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Mn)
    • Segment Trends
    • Cystic Fibrosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Mn)
    • Segment Trends

6. Global Pulmonary Drug Delivery Systems Market, By Regions, 2017 - 2027 (US$ Mn)

    • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2019-2027
    • Segment Trends
    • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Mn)
    • U.S.
    • Canada
    • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

7. Competitive Landscape

    • Company Profiles
    • 3M Health Care
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Allied Healthcare Products, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • AstraZeneca plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Boehringer Ingelheim
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • CareFusion Corporation
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • GF Health Products, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • GlaxoSmithKline plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Merck & Co., Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Omron Healthcare, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Other Major Players
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

8. Section

    • References
    • Research Methodology
    • About us and Sales Contact